Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Thamake, Sanjay; Raut, Sangram; Gryczyński, Zygmunt; Ranjan, Amalendu; Vishwanatha, Jamboor K.

doi:10.1016/j.biomaterials.2012.06.026

Cited by 166 publications

(108 citation statements)

References 37 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…NPs coated with ALD-protected bone resorption and decreased the rate of tumor growth as compared to control groups in an intraosseous model of bone metastasis. They concluded that BPs modified NPs would be a very promising DDS for OP treatment (Thamake et al, 2012).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[16][17][18] Given the fact that biodegradable polymeric NPs elicit negligible side effects, they have been widely investigated for efficient and safe delivery of encapsulated/entrapped chemotherapeutics to the target cells. 17 Of these, poly(lacticco-glycolic acid) (PLGA) is the most studied polymer; [19][20][21] it is also a safe biocompatible polymer in comparison with synthetic polymers/lipids used as delivery systems. [22][23][24] PLGA polymer has previously been used for delivery of insulin 21 and doxorubicin (Adriamycin).…”

Section: Introductionmentioning

confidence: 99%

Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer

Barar

Sandaltzopoulos

Liu

et al. 2014

IJN

View full text Add to dashboard Cite

Conventional chemotherapy of ovarian cancer often fails because of initiation of drug resistance and/or side effects and trace of untouched remaining cancerous cells. This highlights an urgent need for advanced targeted therapies for effective remediation of the disease using a cytotoxic agent with immunomodulatory effects, such as shikonin (SHK). Based on preliminary experiments, we found SHK to be profoundly toxic in ovarian epithelial cancer cells (OVCAR-5 and ID8 cells) as well as in normal ovarian IOSE-398 cells, endothelial MS1 cells, and lymphocytes. To limit its cytotoxic impact solely to tumor cells within the tumor microenvironment (TME), we aimed to engineer SHK as polymeric nanoparticles (NPs) with targeting moiety toward tumor microvasculature. To this end, using single/double emulsion solvent evaporation/diffusion technique with sonication, we formulated biodegradable NPs of poly(lactic-co-glycolic acid) (PLGA) loaded with SHK. The surface of NPs was further decorated with solubilizing agent polyethylene glycol (PEG) and tumor endothelial marker 1 (TEM1)/endosialin-targeting antibody (Ab) through carbodiimide/N-hydroxysuccinimide chemistry. Having characterized the physicochemical and morphological properties of NPs, we studied their drug-release profiles using various kinetic models. The biological impact of NPs was also evaluated in tumor-associated endothelial MS1 cells, primary lymphocytes, and epithelial ovarian cancer OVCAR-5 cells. Based on particle size analysis and electron microscopy, the engineered NPs showed a smooth spherical shape with size range of 120 to 250 nm and zeta potential value of −30 to −40 mV. Drug entrapment efficiency was ~80%–90%, which was reduced to ~50%–60% upon surface decoration with PEG and Ab. The liberation of SHK from NPs showed a sustained-release profile that was best fitted with Wagner log-probability model. Fluorescence microscopy and flow cytometry analysis showed active interaction of Ab-armed NPs with TEM1-positive MS1 cells, but not with TEM1-negative MS1 cells. While exposure of the PEGylated NPs for 2 hours was not toxic to lymphocytes, long-term exposure of the Ab-armed and PEGylated NPs was significantly toxic to TEM1-positive MS1 cells and OVCAR-5 cells. Based on these findings, we propose SHK-loaded Ab-armed PEGylated PLGA NPs as a novel nanomedicine for targeted therapy of solid tumors.

show abstract

“…16 In the last decade, several drug-delivery technologies based on biodegradable polymeric NPs were able to be easily controlled to achieve both active and passive drug targeting after parenteral administration. 17 Increased vascular permeability coupled with damaged lymphatic drainage in tumor tissues allows an enhanced permeability-andretention effect of the NPs at the site of tumors. 18 NPs used as drug carriers have many important advantages, such as high encapsulation efficiency and drug-loading capacity, high stability, sustained release, and excellent feasibility of routes of administration like parenteral and dermal.…”

Section: Introductionmentioning

confidence: 99%

Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy

Zhao¹,

Chen²,

Yan³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:In order to improve the therapeutic efficacy and minimize the side effects of lung cancer chemotherapy, the formulation of paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles (PTX-loaded [PGA-co-PCL]-b-TPGS 2k NPs) was prepared. The novel amphiphilic copolymer (PGA-co-PCL)-b-TPGS 2k was synthesized by ring-opening polymerization and characterized by proton nuclear magnetic resonance spectroscopy and gel permeation chromatography. The PTX-loaded (PGA-co-PCL)-b-TPGS 2k NPs were characterized in terms of size, size distribution, zeta potential, drug encapsulation, surface morphology, and drug release. In vitro cellular uptakes of NPs were investigated with confocal laser scanning microscopy, indicating the coumarin 6-loaded (PGA-co-PCL)-b-TPGS 2k NPs could be internalized by human lung cancer A-549 cells. The antitumor effect of PTX-loaded NPs was evaluated, both in vitro and in vivo, on an A-549 cell tumor-bearing mouse model via intratumoral injection. The commercial PTX formulation Taxol was chosen as the reference. Experimental results showed that the PTX-loaded NPs possessed higher cytotoxicity and could effectively inhibit the growth of tumor. All the results suggested that amphiphilic copolymer (PGA-co-PCL)-b-TPGS 2k could act as a potential biological material for nanoformulation in the treatment of lung cancer.

show abstract

Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Cited by 166 publications

References 37 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer

Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy

Contact Info

Product

Resources

About

Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer

Cited by 166 publications

References 37 publications

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer

Paclitaxel-loaded poly(glycolide-co-&epsilon;-caprolactone)-b-D-&alpha;-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy

Contact Info

Product

Resources

About

Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy